Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus electrochemotherapy for unresectable melanoma
2016-004154-15Phase 2Terminated
- Sponsor
- European Institute of Oncology
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in melanoma, sponsored by European Institute of Oncology. Primary endpoint: Overall response rate. Started Jun 2021; status: terminated.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2016-004154-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004154-15.